Cleveland health care technology company GenomOncology LLC announced that it has added Jonathan Seaton, former senior vice president for corporate and business development at Illumina Inc. (Nasdaq: ILMN), to its board of directors.
The addition of Seaton gives GenomOncology a total of six board members. In a news release, Brad Wertz, the executive chairman of GenomOncology, said Seaton will “provide critical guidance for the road ahead” for the company, which has developed a technology platform to streamline the use of next-generation sequencing data in medical care and research.
Click here to read the complete article.
Story excerpt provided by Crain’s Cleveland Business.
Originally published September 25, 2018.